Two-thirds of the US population, particularly African Americans (AA), is at risk for inadequate or deficient 25-hydroxy-vitamin D (25(OH)VD). Epidemiological studies demonstrate an association between better health outcomes and higher blood levels of 25(OH)VD . Randomized controlled clinical trials have shown that, while supraphysiological high doses of VD are needed to achieve adequate blood levels of 25(OH)VD, not all subjects respond to them. Recent studies have also questioned the therapeutic effects of high-dose VD supplementation. Severe VD deficiency has been associated independently with the future risk of mild cognitive impairment (MCI) and dementia. A reduction in GSH and an increase in the oxidative stress levels of serum, erythrocytes, and circulating lymphocytes has been observed in MCI and Alzheimer disease, findings similar to those in VD deficient persons. Scholarly reviews conclude that excess oxidative stress is one of the major risk factors for AD and support a potential therapeutic role for L-cysteine (LC, a GSH precursor) and vitamin D (VD) supplementation in the treatment of Alzheimer disease symptoms. This application presents the investigators' design for a randomized, double-blind, placebo-controlled clinical trial to test the hypothesis that supplementation with VD in combination with L-cysteine (LC) is more successful at optimizing the statuses of 25(OH)VD [biological signatures] and simultaneously decreasing TNF-α, IR [functional or clinical outcomes], and oxidative stress, suggesting a better therapeutic approach compared with supplementation with VD alone in AA subjects.

开始日期2020-11-06

申办/合作机构

LSU Health Sciences Center

ChiCTR2000032022 / Recruiting早期临床1期IIT

Effect of perioperative nebulized inhalation of budesonide and L-Cysteine on pulmonary complications in patients with tumors of the Posterior Skull Base

开始日期2020-04-30

申办/合作机构-

100 项与 L-半胱氨酸相关的临床结果

登录后查看更多信息

100 项与 L-半胱氨酸相关的转化医学

登录后查看更多信息

100 项与 L-半胱氨酸相关的专利（医药）

登录后查看更多信息

3,651

项与 L-半胱氨酸相关的文献（医药）

2025-02-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Highly selective and sensitive ratiometric detection of Hg2+ ions with NFS co-doped carbon dots: Real sample analysis, antibacterial properties, and cellular imaging applications

Article

作者: Kim, Seong-Cheol ; Palanisamy, Subramanian ; Aslam, Mohammad ; Ahmad, Naushad ; Wahab, Rizwan ; Velu, Kuppu Sakthi ; You, SangGuan ; Mohandoss, Sonaimuthu ; Lee, Yong Rok

A simple, low-cost hydrothermal method was employed to synthesize highly fluorescent nitrogen-, fluorine-, and sulfur-co-doped carbon dots (NFS-CDs) using flufenamic acid and L-cysteine as precursors. The synthesized NFS-CDs exhibited dual emission peaks at 490 and 580 nm with a quantum yield of 24.7 %. They exhibit excellent stability, excitation-dependent fluorescent, and particle sizes ranging from 2 to 8 nm. The fluorescent chemosensor probe, NFS-CDs, showed strong selectivity and sensitivity for Hg²⁺ over other metal ions investigated in aqueous solutions (pH ∼ 7.4). Strong fluorescent enhancement at 490 nm and considerable quenching at 580 nm was observed in the presence of Hg²⁺ ions. The stoichiometric ratio of the NFS-CDs/Hg²⁺ complex was optimized to 1:1 according to the Benesi-Hildebrand and Stern-Volmer plot methods. The NFS-CDs exhibited a linear dynamic detection range from 0 to 10 × 10^-6 M for Hg²⁺ ions with a lower detection limit of 18.0 and 67.5 × 10^-9 M, respectively, at 490 and 580 nm. Practical applications of NFS-CDs in detecting Hg²⁺ ions in natural water samples showed high recovery rates (98.9-104.6 %) and low relative standard deviation (RSD ≤ 2.47 %). The NFS-CDs/Hg²⁺ achieved 78.7 ± 2.6 % and 83.4 ± 2.3 % antibacterial activity against E. coli and S. aureus as NFS-CDs/Hg²⁺ could damage the bacterial walls when they entered the bacteria. Furthermore, the NFS-CDs were used to detect Hg²⁺ ions intracellularly in HCT116 cells with low toxicity using live cell imaging.

2025-02-01·TALANTA

A rewritable and shape memory hydrogel doped with fluorescein-functionalized ZIF-8 for information storage and fluorescent anti-counterfeiting

Article

作者: Ruan, Chaofan ; Shi, Xuan ; Jiang, Qingyuan ; Zhu, Changchang ; Wang, Ni ; Ni, Wang ; You, Rongke ; Ma, Ning ; Tsai, Fang-Chang ; Zeng, Wenyan ; Zeng, Xueling

The emergence of stimuli-responsive fluorescence anti-counterfeiting technology has garnered increasing attention in the era of intelligent internet. Smart fluorescent hydrogels combine the characteristics of luminous materials with the unique structure of hydrogels, offering the potential for dynamic reversible erasing and multi-tiered data encryption. In this work, a fluorescent hydrogel was constructed by zeolitic imidazolate framework-8 loaded with fluorescein and then mixed with polyvinyl alcohol hydrogel, sodium carboxymethyl cellulose and borax, which could be used for image hiding in visible light. The reversible bonds cross-linked fluorescent hydrogel was stretchable and self-healing with a three-dimensional network structure. The hydrogel presented bright green fluorescence under 365 nm UV light, which was quenched by adding copper ions. Meanwhile, the imprint of the hydrogel could be cleared by L-Cysteine and repeatedly recorded information many times. The alkali-induced shape memory capability was further utilized to achieve multi-tiered data encryption by deforming it to a 3D-specific shape through folding. The rewritable and multi-dimensional encrypted hydrogel is expected to improve data security and reduce resource consumption.

2025-01-01·ANALYTICAL BIOCHEMISTRY

Electrocatalytic efficiency of carbon nitride supported gold nanoparticle based sensor for iodide and cysteine detection

Article

作者: Perla, Venkata K ; Mallick, Kaushik ; Ghosh, Sarit K ; Kumari, Pooja ; Saha, Chandan ; Singh, Harishchandra

Extensive investigations are being conducted on gold nanoparticles focusing on their applications in biosensors, laser phototherapy, targeted drug delivery and bioimaging utilizing advanced detection techniques. In this work, an electrochemical sensor was developed based on graphite carbon nitride supported gold nanoparticles. Carbon nitride supported gold nanoparticles (Au-CN) was synthesized by applying a deposition-precipitation route followed by a chemical reduction technique. The composite system was characterized by X-ray diffraction and X-ray photo electron spectroscopy methods. Electron microscopy analysis confirmed the formation of gold nanoparticles within the size range of 5-15 nm on the carbon nitride support. Carbon nitride supported gold based sensor was employed for the electrochemical detection of iodide ion and l-cysteine. The limit of detection and sensitivity of the sensor was attained 8.9 μM and 0.96 μAμM⁻¹cm⁻², respectively, for iodide ion, while 0.48 μM and 5.8 μAμM⁻¹cm⁻², respectively, was achieved for the recognition of cysteine. Furthermore, a paper-based electrochemical device was developed using the Au-CN hybrid system that exhibited promising results in detecting iodide ions, highlighting its potential for economic and portable device applications.

项与 L-半胱氨酸相关的新闻（医药）

2024-10-22

·药通社

【论药海南】专供特色化学原料药-山西阳和药业，涉及呼吸系统、消化系统等领域

2023年12月3-4日 2024MAH&DDS制剂合作大会·海南站展位号：37号公司简介山西阳和药业有限公司成立于2017年，坐落于山西省大同市阳高县龙泉工业园区。公司注册资本5100万元，总占地面积100亩。阳和药业作为化学原料药的商业化生产基地，专业从事特色化学原料药的研发、生产、销售。公司现拥有多条原料药生产线，产品涉及呼吸系统、消化系统等多个领域。目前公司可大批量生产乙酰半胱氨酸、间苯三酚、间苯三酚三甲醚、聚乙烯醇等原料药。 COMPANY PROFILE Shanxi Yanghe Pharmaceutical Co., Ltd. was established in 2017 and is located in Longquan lndustrial Park, Yanggao County, Datong city, shanxi Province. The registered capital of the company is 51 million yuan, and the total area is 100 acres.As a commercial production base of chemical APls, Yanghe Pharmaceutical specializes in the R&D, production and sales of specialty chemical APls. The company now has a number of API production lines, and its products involve respiratory system, digestive system and other fields. At present,the company can produce acetylcysteine, resorcinol, and resorcinol trimethyl ether in large quantities, polyvinyl alcohol and other APls. 公司团队公司拥有一支年轻有干劲的新型团队；建立了完善的生产和质量管理体系；公司建有多个原料药多功能车间，实现从小试研究、中试放大、注册申报、大规模生产的一条龙服务；严格的质量控制，完善的检验设施和仪器设备，严密的质量保证系统，能够有效保障法规符合性、CFDl注册核查和客户审计的要求。 COMPANY TEAM The company has a young and energetic new team, has established a sound production and QMS system, the company has built a number of APl multifunctional workshops, to achieve a small test research, pilot scale-up, registration declaration, large-scale production one-stop service, strict QC, perfect inspection facilities and equipment, strict QA system, can effectively ensure regulatory compliance,CFDl registration verification and customer audit requirements. 01 乙酰半胱氨酸化学名：N-乙酰基-L-半胱氨酸 CAS No.: 616-91-1 登记号：Y20210001235 用途：呼吸系统药物，具有祛痰的作用，其注射液用于肝衰竭早期治疗，也可用于配置复合氨基酸输液、特医食品及保健品。符合ChP2020年版、BP2022、EP10.8、JPX VlII、USP-NF2022药典标准；已获得GMP、CP Chemical name: N-acetyl-L-cysteine CAS No.: 616-91-1 Registration No.: Y20210001235 Uses: Respiratory system drug, with expectorant effect, its injection for the early treatment of liver failure, can also be used to configure complex amino acid infusion, special medical food and health care products. In accordance with ChP2020、BP2022、EP10.8、JPX VlII、USP-NF2022；GMP and CP have been obtained 02 间苯三酚三甲醚化学名：1，3，5-三甲氧基苯 CAS NO.: 621-23-8 登记号：Y20220000338 用途：消化系统和胆道功能障碍引起的急性痉挛性疼痛；急性痉挛性尿道、膀胱、肾绞痛；妇科痉挛性疼痛已获得GMP、CP Chemical name: 1,3,5-Trimethoxybenzene CAS No.: 621-23-8 Registration No.: Y20220000338 Uses: Acute spasmodic pain caused by digestive system and biliary tract dysfunction; Acute spastic colic of urethra, bladder and kidney; Gynecologic spasmodic pain GMP and CP have been obtained 03 间苯三酚化学名：苯基-1，3，5-三酚二水合物 CAS No.: 6099-90-7 登记号：Y20220000471 用途：消化系统和胆道功能障碍引起的急性痉挛性疼痛；急性痉挛性尿道、膀胱、肾绞痛；妇科痉挛性疼痛符合BP2022、EP10. 8药典标准；已获得GMP、CP Chemical name: Benzene-1,3,5-triol dihydrate CAS No.: 6099-90-7 Registration No.: Y20220000471 Uses: Acute spasmodic pain caused by digestive system and biliary tract dysfunction; Acute spastic colic of urethra, bladder and kidney; Gynecologic spasmodic pain In accordance with BP2022, EP10.8；GMP and CP have been obtained 04 聚乙烯醇化学名：聚乙烯醇 CAS NO.: 9002-89-5 用途：用于润滑和滋润眼睛表面，有助于暂时缓解干眼症（DED）或环境因素引起的干燥、刺激、灼热、不适和/或任何其他症状符合ChP2020年版、BP2022、EP10.8、USP-NF2022药典标准；已获得GMP Chemical name: Poly(vinyl alcohol) macromolecule CAS No.: 9002-89-5 Use: To lubricate and moisturize the surface of the eye to help temporarily relieve dryness, irritation, burning, discomfort and/or any other symptoms of dry eye (DED) or environmental factors。 In accordance with ChP2020、BP2022、EP10.8、USP-NF2022；GMP have been obtained 联系方式周女士13306586060 薛女士15958675001 点击查看大会详情 ▽ 立即扫码报名 ▽

2023-10-31

·靶点社

燃爆资本市场，减肥药最新进展：华东医药、普利制药、翰宇药业

▲12月16-17日【CCC 2023】临研天下 · 限时免费报名中声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。肥胖或为“万恶之源”。肥胖对个人健康造成严重威胁，和高血压、糖尿病、高血脂等多种慢性疾病呈现显著正相关，为健康的“万恶之源”。减肥药消费属性强，空间大，有“药王”潜质。美国资本市场高度认可，诺和诺德和礼来，落霞与孤鹜齐飞，市值飙升到4000-5000亿美元，国内相关概念股也是纷纷异动。GLP-1类药物已成为肥胖首选药物，国际巨头已推动GLP-1类药物其他适应症开发，如NASH、阿尔兹海默、外周心血管疾病、慢性肾病、心衰和睡眠呼吸暂停综合征以及延长寿命等，想象空间巨大。据德邦证券，依据《中国居民肥胖防治专家共识》的统计数据，中国成年人中超重及肥胖人群占比过半，预计国内人群超6亿人。目前国际资本市场都在等待礼来和诺和诺德的三季报，国内的投资机构忙调研，我们选取三家公司调研纪要，看看他们的减肥药相关业务最新进展。2023 年10月24日到25日，超过百家投资机构对华东医药（000963）和普利制药（300630）进行了调研，10月11日90多家机构对翰宇药业（300199）进行了调研。GLP-1管线进度和利拉鲁肽销售情况2023年1-9月公司合计实现营业收入303.95亿元，同比增长9.10%；实现归属于上市公司股东的扣非净利润21.60亿元，同比增长13.62%。（1）GLP-1 管线的进度？答：公司以 GLP-1 靶点为核心，已建立了涵盖口服、注射剂等多种剂型包括长效和多靶点全球创新药和生物类似药相结合的 GLP-1 及相关靶点管线产品。生物类似药方面，公司利拉鲁肽注射液糖尿病适应症及肥胖或超重适应症分别在今年 3 月和 6 月在国内获批上市，是公司在 GLP-1 领域的第一个获批产品；司美格鲁肽注射液糖尿病适应症的Ⅲ期临床已于 2023 年 9 月完成首例受试者入组，公司后续也计划在国内启动减肥适应症的临床试验。创新药方面，公司自主研发的口服小分子 GLP-1 受体激动剂 HDM1002 糖尿病适应症已于 2023 年 6 月初实现首例受试者用药，肥胖适应症的中国 IND 申请已于 2023 年 9 月获批；公司自主研发的 GLP1R/GIPR 双靶点长效多肽类激动剂 HDM1005 预计 2024 年初递交 IND 申请。控股子公司道尔生物在研的 GLP-1R/GCGR/FGF21R 靶点的多重激动剂 DR10624 正在新西兰开展肥胖症的 I 期 MAD 临床试验，用于超重或肥胖人群的体重管理的中国 IND 申请已于 2023 年 7 月获批，并于 2023 年 10 月完成了中国 I 期 SAD 的首个队列（共 12 位受试者）给药。糖尿病适应症的中国 IND 申请已于 2023 年 9 月获批。重度高甘油三酯血症适应症的中国 IND 已于 2023 年 8 月递交。（2）利拉鲁肽目前入院和销售情况？答：公司利拉鲁肽注射液糖尿病适应症及肥胖或超重适应症分别在今年 3 月和 6 月在国内获批上市，作为公司在 GLP-1 领域的第一个获批产品，公司也十分重视该产品的上市推广和市场渠道覆盖工作。截至目前，公司利拉鲁肽注射液已在国内几百家大型医院实现入院销售，数量还在快速增长中。此外，院外市场也是减肥适应症的主要销售渠道，包括线上平台及线下药店，公司也在积极进行布局。目前合作开发的连锁药店的总部数量已经接近 200 家，国内的百强连锁已经基本完成开发和覆盖，或完成沟通谈判，目前正在积极的铺货中，计划在年内完成 3 万家终端铺货单体药店数量的目标。（3）公司 GLP-1 相关产能布局？答：公司利拉鲁肽和司美格鲁肽均为自主生产，利拉鲁肽目前是由中美华东租赁九源基因相关生产场地，在九源基因生产。司美格鲁肽规划在公司位于杭州钱塘新区的的江东项目二期的生产基地进行生产。随着研发进度的推进，以及产品后续市场需求变化，公司会动态进行产能规划，提前布局，以保证市场的稳定供应。多肽基于合成生物学的发酵车间（1）合成生物学方法生产司美格鲁肽优势？司美格鲁肽合成方法主要有化学合成和合成生物学发酵法两种，其中合成生物学发酵法包括酵母发酵和大肠杆菌发酵，公司有两种发酵合成方法均有储备。采用合成生物学生产司美格鲁肽有两大优点：一是化学合成法会受到规模的限制，产量受限，合成生物学法可以满足大规模生产要求，二是通过合成生物学方法具备明显成本优势，尤其是固体制剂的使用中优势会更加明显。（2）多肽产品产能建设情况？公司的多肽主要是基于合成生物学的发酵车间，目前 12 吨发酵已测试完毕，正在试生产阶段，后续规划会进一步扩展到 50 吨发酵体系。（3）合成生物学除了司美格鲁肽的其他品种研发进度？合成生物学方向，除了司美格鲁肽外，还有依克多因、红景天苷已进入放大生产阶段，研发中的包括熊去氧胆酸、西格列汀、L-半胱氨酸等项目在持续推进中，公司未来会在合成生物学方向持续积累产品。（4）公司在口服司美格鲁肽竞争优势和业务进展？口服司美格鲁肽按计划推进中，公司已经攻克了辅料 SNAC，实现了放大化生产，关键理化指标符合项目要求。公司计划在司美格鲁肽原料药、辅料、针剂、固体都全面向前推进，做到规模和成本上有优势，并且进行全球注册。（5）司美格鲁肽立项的思路？考虑患者人群基础，降糖、减肥市场足够大，而且可以降低很多疾病的发生，如果用量全部铺开，需求会超过百吨级以上，合成生物学会更有机会。根据需求和未来增长分析，司美格鲁肽和替尔泊肽都具有一定潜力，考虑未来疾病发展趋势以及公司本身在合成生物学、纯化技术上的优势，公司攻克原料药的同时，制剂也会一起做。“减肥药”产品布局和项目进展情况（1）公司最近对“国际化”战略提及比较多，国际化发展方面都有哪些重大举措？答：公司成立至今二十余年，专注做好一件事情：多肽药物。并始终坚持“立足中国，放眼全球”的“国际化”发展战略。我们是为数不多的A股多肽上市公司里，最终能获得美国大药企认可，将商业批的GLP-1多肽原料药成功销往美国，9月签下折合2.19亿元大订单的公司，且已进入分批生产和发货状态，为了忙着生产备货，生产线的员工每天三班倒，很辛苦，但大家都很开心，得到美国大药厂的认可，是全公司上下这么多年来共同努力的结果！最近，与国际多肽创新药物领军企业辉凌医药（Ferring Pharma）就多肽药品达成了一项覆盖全球78个国家和地区的合作推广协议。很快，我们还会有更多多肽原料药、GLP-1重磅多肽制剂、多肽药物给药用的注射笔（医疗器械）陆续在全球上市，这是一件振奋人心的事情！二十多年来公司以多肽药物研发、生产、销售为核心，紧抓国际市场机遇，多个原料药及制剂“中美欧三报”。并且在过去已经有成功在海外获批的经验，包括有多肽注射剂依替巴肽成功获得美国FDA批准上市、阿托西班欧盟批准上市，除此之外，国际管线还布局了高技术壁垒的利拉鲁肽、西曲瑞克、格拉替雷、司美格鲁肽、替尔泊肽、特立帕肽、阿巴帕肽等重磅多肽制剂；美国FDA完成了对我司多肽原料药生产基地及多肽制剂生产基地现场核查，“国际化”战略下公司稳步推进相关业务，为公司长远经营发展筑牢基础，我们对公司未来非常有信心。（2）请介绍下公司在“减肥药”产品布局和项目进展情况。答：公司在多肽减重降糖管线布局有：替尔泊肽、司美格鲁肽（口服、注射剂都有布局）、利拉鲁肽、艾塞那肽、二甲双胍缓释片、西格列汀二甲双胍、维格列汀、笔式注射器等，其中， GLP-1多肽原料药已经收获了海外制药企业商业批订单、GLP-1 重磅制剂美国FDA申报已进入最后审评阶段；司美格鲁肽在中国已收到国家药品监督管理局签发的临床试验注册申请《受理通知书》。公司正在积极推进相关产品的研发及注册申报工作除了上述药品级的产品，我们还在拓展多肽新零售业务，包括有减肥用的多肽食品、助眠功能的多肽产品、降尿酸功能的多肽食品等。参考资料：德邦证券各公司纪要

临床3期财报生物类似药

100 项与 L-半胱氨酸相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
寻常痤疮	日本	Hisamitsu Pharmaceutical Co., Inc.	1987-05-23
药物性皮炎	日本	Hisamitsu Pharmaceutical Co., Inc.	1987-05-23
湿疹	日本	Hisamitsu Pharmaceutical Co., Inc.	1987-05-23
渗出性红斑	日本	Hisamitsu Pharmaceutical Co., Inc.	1987-05-23
白细胞减少	日本	Hisamitsu Pharmaceutical Co., Inc.	1987-05-23
荨麻疹	日本	Hisamitsu Pharmaceutical Co., Inc.	1987-05-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2006	N/A	-	100	Cistein	鏇築願襯壓觸醖製糧顧(簾夢齋顧齋醖餘網餘觸) = 簾廠構築鹽餘鹹構獵壓廠遞衊鹹構鏇選膚網窪 (願選蓋構醖夢壓鑰簾鑰 ) 更多	积极	2006-05-01
				Cistein	鏇築願襯壓觸醖製糧顧(簾夢齋顧齋醖餘網餘觸) = 積網鏇觸蓋艱構膚淵醖廠遞衊鹹構鏇選膚網窪 (願選蓋構醖夢壓鑰簾鑰 ) 更多